A new probe developed uses an innovative fluorescence-reading technology to help brain surgeons distinguish cancerous tissue from normal tissue. The probe tool, now already in use at the Cancer Center for brain surgery, may one day be used for surgeries for a variety of cancers.
Researchers discovered that some cases of glioblastoma, the most common and aggressive form of primary brain cancer, are caused by the fusion of two adjacent genes. The study also found that drugs that target the protein produced by this genetic aberration can dramatically slow the growth of glioblastomas in mice.
“We identified a subset of brain tumor cells that are slower growing or remain at rest, and appear to be the source of cancer recurrence after standard therapy in which the drug temozolomide is given to stop the tumor’s growth,” said Dr. Luis Parada. “Current therapy targets fast-growing tumor cells but not those responsible for new tumors. To the best of our knowledge, this is the first identification of a cancer stem-like cell in a spontaneously forming tumor inside a mammal.”
When aggressive, malignant tumors appear in more than one location in the brain, patient survival tends to be significantly shorter than when the disease starts as a single tumor, even though patients in both groups undergo virtually identical treatments, according to research at Cedars-Sinai Medical Center's Maxine Dunitz Neurosurgical Research Institute.
Researchers have discovered two gene variants that raise the risk of the pediatric cancer neuroblastoma. This is the first study to link known cancer-related genes HACE1 and LIN28B to neuroblastoma. The study broadens understanding of how gene changes may make a child susceptible to this early childhood cancer, as well as causing a tumor to progress.
Researchers have shown that infrared and Raman spectroscopy – coupled with statistical analysis – can be used to tell the difference between normal brain tissue and the different tumor types that may arise in this tissue, based on its individual biochemical-cell ‘fingerprint’.
Scientists have long believed that glioblastoma multiforme, the most aggressive type of primary brain tumor, begins in glial cells that make up supportive tissue in the brain or in neural stem cells. Researchers found that the tumors can originate from other types of differentiated cells in the nervous system, including cortical neurons.
In a study published in Neuro-Oncology, researchers at Mayo Clinic identify an important association between the naturally occurring enzyme Kallikrein 6, also known as KLK6, and glioblastoma multiforme tumors.
Researchers discover the genetic landscape of the most common form of brain tumor can be explained by abnormalities in five genes. The finding could help to develop personalized medical therapies and treatment options.
A new study discovers molecular pathways that could lead to new targeted therapies which may potentially treat Glioblastoma, the most common and lethal form of brain cancer in adults.